Zobrazeno 1 - 10
of 56
pro vyhledávání: '"György, Horvath"'
Autor:
Ram K. Gupta, Felipe M. de Souza, Muhammad Rizwan Sulaiman, Ziwei Li, Kaimin Chen, Mingwei Wang, Mattia Bartoli, Giulio Malucelli, Alberto Tagliaferro, Tuhin Ghosh, Niranjan Karak, Young Nam Kim, Hyunsung Jeong, Sooyeon Ryu, Yong Chae Jung, Mesut Genisoglu, Sait C. Sofuoglu, Aysun Sofuoglu, Nycolle G. S. Silva, Noelle C. Zanini, Alana G. de Souza, Rennan F. S. Barbosa, Derval S. Rosa, Daniella R. Mulinari, Saptaparni Chanda, Dilpreet S. Bajwa, Emad S. Goda, Mahmoud H. Abu Elella, Heba Gamal, Sang Eun Hong, Kuk Ro Yoon, Wen-Jie Yang, Chun-Xiang Wei, Hong-Dian Lu, Wei Yang, Richard K. K. Yuen, K. M. Faridul Hasan, Péter György Horváth, Seda Baş, Tibor Alpár, Marcin Włoch
Publikováno v:
Oncology Letters
The purpose of this study was to compare the toxicity profiles of docetaxel administered on a weekly schedule and the standard three-week schedule in the treatment of advanced primary ovarian carcinoma. Eligible patients were treated with intravenous
Autor:
Karin Boman, Håkan Andersson, György Horvath, Caroline Lundgren, Bengt Sorbe, Birgitta Pettersson
Publikováno v:
International Journal of Gynecologic Cancer. 22:1281-1288
BackgroundA combination of vaginal brachytherapy and external beam radiotherapy was compared with brachytherapy alone in medium-risk endometrial carcinomas. Quality-of-life analysis is an important part of a randomized study to find out the optimal a
Autor:
Marianne Graflund, Bengt Sorbe, Margareta Lood, Karin Boman, Marie Swahn, Henric Malmström, Rene Bangshoj, György Horvath
Publikováno v:
International Journal of Gynecologic Cancer. 22:47-53
ObjectivesThe purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carbo
Autor:
Lovisa Österberg, Ulla Delle, Björn Olsson, Saskia Eklind, Kristina Levan, György Horvath, Karolina Partheen
Publikováno v:
Gene Expression. 14:361-370
Endometrial cancer is the most common malignancy of the female reproductive tract. In many cases the prognosis is favorable, but 22% of affected women die from the disease. We aimed to study potential differences in gene expression between endometrio
Autor:
Lovisa Österberg, Johan Staaf, Karolina Partheen, Karin Sundfeldt, Kristina Levan, György Horvath
Publikováno v:
Cytogenetic and Genome Research. 125:8-18
Chemotherapy resistance remains a major obstacle to successful treatment of ovarian cancer patients. Therefore, increased knowledge of underlying mechanisms and identification of predictive factors are of great importance. Standard treatment for ovar
Autor:
Karin Sundfeldt, Karolina Partheen, Kristina Levan, Ghita Fallenius, György Horvath, Ingela Claesson, Lovisa Österberg
Publikováno v:
International Journal of Cancer. 123:2130-2137
The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein e
Publikováno v:
Journal of Pharmaceutical Sciences. 97:2045-2048
P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Recently, the G1199T/A polymorphism in the ABCB1 gene was shown to be important for the function of P-gp a
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 87:1343-1352
To evaluate long-term survival and prognostic factors for all epithelial ovarian cancer (EOC) patients after adjuvant treatment with paclitaxel and carboplatin.Prospectively collected data from a population-based cohort.Western Sweden Health Care Reg
Autor:
Britt-Marie Zetterqvist, György Horvath, Margaretha Åkeson, Kristina Levan, Karolina Partheen, Mats Brännström, Lovisa Österberg
Publikováno v:
Cancer Genetics and Cytogenetics. 167:103-108
Borderline tumors of the ovary comprise 10-20% of all epithelial ovarian tumors, and are placed between clearly benign and obviously malignant ovarian tumors. The issue of whether borderline tumors are precursors of invasive carcinoma or distinct cli